≥98% (HPLC)

BAY68-4986, 2-Amino-6-2-(4-chlorophenyl)-4-thiazolylmethylthio-4-4-(2-hydroxyethoxy)phenyl-3,5-pyridinedicarbonitrile, 2-Amino-6-2-(4-chlorophenyl)-1,3-thiazol-4-ylmethylsulfanyl-4-4-(2-hydroxyethoxy)phenylpyridine-3,5-dicarbonitrile, BAY 68-4986, BAY-68-4986
Empirical Formula (Hill Notation):
Número de CAS:
Peso molecular:
MDL number:
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level


≥98% (HPLC)




white to beige


DMSO: 2 mg/mL, clear

storage temp.


SMILES string


Biochem/physiol Actions

Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPγS binding EC50/Emax = 0.1 nM/74% vs. 0.3 nM/100% with CCPA; human cortex membranes) that exerts additional biased A2BAR agonism toward cAMP signal transduction (pEC50 = 8.94/cAMP, 6.20/Ca+2, 6.12/pERK, 5.03/IP1), while exhibiting weak A2A & A3 potency. Capadenoson offers cardioprotection efficacy in an ischemia-reperfusion injury rat model in vivo (25/28% infarct size reduction with 0.1/0.3 mg/kg iv.) without the risk of a full atrioventricular (AV) block (isolated perfused rat heart rate = 100% up to 10 nM, 90% at ≥10 μM) seen with the full A1 agonist CCPA.

WGK Germany


Flash Point F

Not applicable

Flash Point C

Not applicable

Jo-Anne Baltos et al.
Biochemical pharmacology, 135, 79-89 (2017-03-28)
The adenosine A2B receptor (A2BAR) has been identified as an important therapeutic target in cardiovascular disease, however in vitro and in vivo targeting has been limited by the paucity of pharmacological tools, particularly potent agonists. Interestingly, 2-((6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)-2-pyridinyl)thio)acetamide (BAY60-6583), a potent...
Isaac R Bailey et al.
The Journal of pharmacology and experimental therapeutics, 362(3), 424-430 (2017-06-28)
Cardiac arrest is a leading cause of death in the United States, and, currently, therapeutic hypothermia, now called targeted temperature management (TTM), is the only recent treatment modality proven to increase survival rates and reduce morbidity for this condition. Shivering...
Barbara E Albrecht-Küpper et al.
Purinergic signalling, 8(Suppl 1), 91-99 (2011-11-15)
Adenosine, a purine nucleoside, is present in all cells in tightly regulated concentrations. It has many different physiological effects in the whole body and in the heart. Adenosine activates four G protein-coupled receptors A1, A2a, A2b, and A3. Activation of...
Daniel Meibom et al.
ChemMedChem, 12(10), 728-737 (2017-05-11)
Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1 Rs) has been shown to inhibit myocardial pathologies associated...
Samantha L Cooper et al.
British journal of pharmacology, 177(2), 346-359 (2019-10-10)
Adenosine is a local mediator that regulates physiological and pathological processes via activation of four GPCRs (A1 , A2A , A2B , and A3 ). We have investigated the effect of two A1 -receptor-selective agonists and the novel A1 -receptor...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.